Navigation Links
DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus
Date:6/17/2013

HOUSTON, June 17, 2013 /PRNewswire/ -- DNAtrix Inc., experts in oncolytic virus development, today announced that its CEO will present clinical data on the company's lead product, DNX-2401, at the Replicating Oncolytic Virus Therapeutic meeting in Quebec City, Canada on June 18, 2013.

Dr. Frank Tufaro, DNAtrix's CEO and a leader in the field of oncolytic virus therapy, will present results from a clinical study entitled A PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN AS DELTA-24-RGD) FOR RECURRENT MALIGNANT GLIOMAS that evaluated DNX-2401 for patients diagnosed with recurrent glioblastoma. Dr. Tufaro will present study data indicating that DNX-2401 has been well tolerated in 37 patients with no dose-limiting toxicity. Additionally, DNX-2401 has demonstrated highly impressive activity and efficacy.

"We are extremely pleased to have participated in bringing DNX-2401 into the clinic, and are encouraged by the results from this clinical study," said Dr. Tufaro. "DNX-2401 has not only revealed a positive safety profile but also an ability to selectively kill glioblastoma cells. This is exciting because it can lead to complete tumor destruction."

About Glioblastoma and DNX-2401
Glioblastoma is a devastating primary brain tumor resistant to conventional therapies and the second most common cause of death from intracranial disease. The lack of effective therapy for brain tumors has led to intense investigations of novel therapeutic approaches that use vectors and recombinant viruses. Oncolytic virus therapy is based on the concept of using live viruses to selectively infect and replicate in cancer cells, with minimal destruction of normal tissue. Replication amplifies the input dose of the oncolytic virus and helps spread the agent to adjacent tumor cells. DNX-2401, a conditionally replication-competent adenovirus, is being developed for the treatment of several cancer indications including patients with recurrent glioblastoma. DNX-2401 is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date.  DNAtrix will initiate a Phase II clinical study later this year.

About DNAtrix, Inc.
DNAtrix is a company developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company located in Houston, Texas and San Diego, California. For more information, please visit the Company's website at http://www.dnatrix.com.

DNAtrix, Inc. Contact
Frank Tufaro, Ph.D.
Chief Executive Officer
ftufaro@dnatrix.com
(858) 342-6577


'/>"/>
SOURCE DNAtrix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
8. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):